Past Performance: Past Performance is not an indicator of future results.
Bionano Genomics Inc. (BNGO) is a life-science instrumentation company focussed on the study of genetics for applications in the academic and medical fields. Headquartered in San Diego, California, Bionano's featured product is its proprietary Saphyr genome mapping system. Core business segments involve the production of Saphyr optical genome mapping instruments, nanochannel chips, prep kits and data solutions.[1]
Shares of BNGO stock are listed for trade on the NASDAQ exchange. As of March 2021, BNGO held a market capitalisation of US$1.65 billion, with more than 180 million shares outstanding.[2] Amid the initial stages of the COVID-19 pandemic, BNGO posted a trading range of US$0.25-US$15.69 from March 2020 to March 2021.[2]
NFT mania is here. What do you need to know? Digital art has always been something pretty cool but has reached a new level recently with NFT mania. It seems…
As we have entered the second half of the year, many high- profile companies have already reported their financial results and some of them have stood out
Although the UK100 is off of its pandemic lows it has lagged other indexes such as the GER30 and SPX500. Nevertheless, there are certainly companies which are performing well with…
After the markets close on Monday August 30th, Zoom Video Communications Inc (ZM.us) will release its financial results for the three-month period that ended in July (Q2 FY2022).
The second quarter earnings season was very good with over 80% of S&P 500 companies reporting an earnings surprise. Moreover, stock indexes performed strongly with FXCM's SPX500 up 8.25%, the…
NIO Inc. (NIO.us) reported solid financial results for the second quarter of the year , after the US markets closed last Wednesday
|
Retrieved 21 Mar 2021 https://bionanogenomics.com/products/ |
|
|
Retrieved 21 Mar 2021 https://www.cnbc.com/quotes/BNGO |
|
Retrieved 21 Mar 2021 https://bionanogenomics.com/products/ |
|
|
Retrieved 21 Mar 2021 https://www.cnbc.com/quotes/BNGO |
FXCM can be compensated in several ways, which includes but are not limited to adding a mark-up to the spreads it receives from its liquidity providers, adding a mark-up to rollover, etc. Commission-based pricing is applicable to Active Trader account types.
Risk Warning: Our service includes products that are traded on margin and carry a risk of losses in excess of your deposited funds. The products may not be suitable for all investors. Please ensure that you fully understand the risks involved.
Exchange: ${getInstrumentData.exchange}
${getInstrumentData.bid} ${getInstrumentData.divCcy} ${getInstrumentData.priceChange} (${getInstrumentData.percentChange}%) ${getInstrumentData.priceChange} (${getInstrumentData.percentChange}%)
Any opinions, news, research, analyses, prices, other information, or links to third-party sites contained on this website are provided on an "as-is" basis, as general market commentary and do not constitute investment advice. The market commentary has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is therefore not subject to any prohibition on dealing ahead of dissemination. Although this commentary is not produced by an independent source, FXCM takes all sufficient steps to eliminate or prevent any conflicts of interests arising out of the production and dissemination of this communication. The employees of FXCM commit to acting in the clients' best interests and represent their views without misleading, deceiving, or otherwise impairing the clients' ability to make informed investment decisions. For more information about the FXCM's internal organizational and administrative arrangements for the prevention of conflicts, please refer to the Firms' Managing Conflicts Policy. Please ensure that you read and understand our Full Disclaimer and Liability provision concerning the foregoing Information, which can be accessed here.